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Abstract 
Cortisol is transported in the blood by corticosteroid-binding globulin (CBG), a non-inhibitory member 
of the serpin family of serine protease inhibitors. Recent structural advances reveal how CBG acts as a 
releasing-agent as well as a carrier of cortisol. Taken together, the structures of the various forms of 
CBG and of the closely related thyroxine binding-globulin, show how the inherent conformational 
mechanism of the serpins has been adapted to modulate hormone release to the tissues by changes in 
binding affinities. A deduction from this, of the temperature dependence of hormone binding, is 
remarkably borne out with CBG, with a doubling in plasma free cortisol as the body temperature rises 
to 39oC. Another insight, against a dogma in the corticosteroid field, is that the proteolytic cleavage of 
CBG in inflammation results in a partial and not a complete loss of cortisol binding. This becomes of 
medical importance in conjunction with recent evidence of a pool of the circulating cleaved-form of 
CBG. It is now evident that tissue levels of free cortisol are buffered by two responsive plasma pools, 
intact CBG with a high binding-affinity and, particularly in inflammation and sepsis, a further pool of 
cleaved-CBG with a ten-fold lower affinity. The new molecular understandings, as well as providing 
insights into the differential release of circulating hormones, also open prospects for therapeutic 
interventions and draw attention to the potential of CBG and TBG as vehicles for the targeted delivery 
of drugs. 
 
Abreviations 
CBG – corticosteroid-binding globulin, TBG – thyroxine-binding globulin 
 
Key Words 
CBG, cortisol, serpin, TBG, body temperature, inflammation. 
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1. Introduction 
 
Of the total cortisol in the blood, only some 5% is present in its active free form with the other 95% 
being inertly bound to plasma proteins, primarily to its specific transport protein, corticosteroid-binding 
globulin (CBG) (Hammond, 1990; Lewis, et al., 2005; Westphal, 1986). The CBG-bound cortisol acts 
as a circulating store but critically it is the equilibrated release of cortisol from CBG that buffers and 
regulates the plasma concentration of free cortisol. Cortisol is carried by CBG in a 1:1 ratio and its 
release of free cortisol will follow the law of mass action, being determined by two factors, the 
percentage saturation of the CBG and by its cortisol-binding affinity.  The percentage saturation will 
vary with the adrenal secretion of cortisol, which at peak times can exceed the binding capacity of CBG 
resulting in disproportionately high levels of free cortisol (Henley & Lightman, 2011; Young, et al., 
2004). For the most part though, a steady state concentration of cortisol throughout the tissues is 
maintained with the binding capacity of CBG being only partially saturated. For example in a healthy 
adult a typical free cortisol concentration of 13nM (Ho, et al., 2006) will result from a 29% saturation 
of CBG. This then, till recently, has been the accepted role of CBG as a simple carrier of cortisol that 
gives an equilibrated release of the hormone to maintain uniform free cortisol concentrations throughout 
the tissues. The assumption has been that the cortisol-binding affinity of CBG remains a constant 
throughout. 
This assumption of a constant binding-affinity has been overturned, as we describe here, by recent 
findings and particularly from structure-based studies of CBG and of the closely related carrier of 
thyroxine, thyroxine-binding globulin (TBG) (Gardill, et al., 2012; Klieber, et al., 2007; Qi, et al., 2011; 
Zhou, et al., 2006; Zhou, et al., 2008). Both CBG and TBG have virtually identical hormone binding 
sites and hormone release mechanisms. The surprise conclusion from structural studies of both, is that 
hormone binding and release is not an on-off event but rather represents an equilibrated change in 
binding avidity that can be allosterically modulated. Put simply, the cortisol binding-affinity of 
circulating CBG, and hence the concentration of free cortisol, is not fixed and can be modified by 
 6 
 
external factors. This immediately makes good biological and physiological sense. A human is a 
complex assemblage of organs, each of which will have at times different hormone requirements. We 
give two examples here of the way CBG can respond to such varying needs by a change in its cortisol-
binding affinity: locally in inflammation and systemically in fevers. Although these are at present the 
only proven examples of the modulatory role of CBG, there is good reason to predict that such 
responsive changes in binding-affinity will more widely occur by direct interaction with tissue 
membranes and ligands. 
 
2.   Corticosteroid binding globulin 
2.1  Plasma CBG 
Corticosteroid-binding globulin (CBG), or transcortin, has become well documented as the 50-60 kDa 
high affinity plasma transport glycoprotein for the glucocorticoid hormones, principally cortisol 
(Westphal, 1986). It can also bind progesterone with relatively high affinity, however the amounts 
bound to CBG in the peripheral circulation are relatively low compared with glucocorticoids (Cameron, 
et al., 2010; Rosner, 1990). CBG is secreted principally from hepatocytes (Khan, et al., 1984), as a 383-
residue polypeptide after cleavage from a 22-amino-acid signal peptide. Functionally, CBG was known 
to be monomeric, to have a single steroid binding site per molecule (Mickelson, et al., 1982; Westphal, 
1986), to circulate at concentrations of 175-365 nmol/L (Nenke, et al, 2016) and in keeping with this, 
to become saturated at plasma cortisol levels above 400-500 nmol/L (Ballard, 1979). 
Although all this was known, a central puzzle remained. The rate of production of cortisol and its plasma 
concentration are poorly correlated, with CBG apparently being involved in determining the kinetics of 
cortisol transport from plasma to tissue (Bright, 1995; Bright & Darmaun, 1995). The question facing 
the field was how does CBG play this active role in the release of cortisol as well as in its transport? 
The answer came in a most satisfying way with the determination, at molecular level, of the way CBG 
binds cortisol and of the structural changes that influence its release (Klieber, et al., 2007; Zhou, et al., 
2008). Not only is CBG seen to act as a circulating glucocorticoid reserve readily available in case of 
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an emergency (Moisan, 2013) but also, importantly, to have an inbuilt mechanism that modulates its 
glucocorticoid release (Chan, et al, 2013; Lin, et al., 2010; Qi, et al., 2011; Zhou, et al., 2008). 
2.2  What structures tell us about hormone carriage and release 
Advances over the last two decades have seen a transformation of fundamental concepts in 
endocrinology, from a descriptive to a precise molecular basis. What has made this possible has been 
the realisation that proteins, even with quite different functions, exist as members of a discrete number 
of families, with each family sharing the same overall structure. Thus knowledge of the structure and 
function of any one member of a protein family is of relevance to all the members. This is well borne 
out by the carriers of thyroxine and cortisol in the blood, TBG and CBG. Both are members of the 
serpin family of proteins (Flink, et al., 1986; Hammond, et al., 1987), having almost identical structures 
and molecular mechanisms. Furthermore, the archetype of the serpin family and a coding neighbour to 
CBG on chromosome 14, was another plasma protein, of known crystallographic structure, alpha1-
antitrypsin. Unlike TBG and CBG, which have both lost their inhibitory activity, alpha1-antitrypsin has 
retained its eponymous serpin function as a serine protease inhibitor. The predominance of the serpins 
as protease inhibitors in the blood is due to their unique spring-like action that has been realistically 
likened to that of a molecular mousetrap. The active inhibitor circulates in a stressed S-form, which 
readily springs back into a stable relaxed R-form to give the entrapment of the target protease (Carrell 
& Owen, 1985; Huntington, et al., 2000); the entrapment being triggered by the cleavage of a large 
exposed peptide loop by the protease, as indicated in Figure1. 
The confirmation from their amino acid sequences that TBG and CBG were serpins allowed the ready 
modelling of their molecular structure on the known template of alpha1-antitrypsin (Huber & Carrell, 
1989) and subsequently of the hormone binding site in CBG (Edgar & Stein, 1995). TBG and CBG 
have both lost any function as protease inhibitors but have clearly retained the overall serpin 
conformational mechanism, with both hormone carriers undergoing the S-to-R conformational change 
on exposure to inflammatory proteases (Pemberton, et al, 1988). This transition was seen to be 
accompanied by a loss of hormone binding affinity, though even in these early findings it was noted 
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that the loss of binding affinity in CBG was incomplete. Further studies confirmed the deduction that 
the release of cortisol in response to cleavage by neutrophil proteases represented a mechanism for the 
delivery of the hormone to inflammatory loci (Hammond, et al., 1990).  
An assumption made by many from these early studies was that the binding and release of thyroxine 
and cortisol from their carrier proteins was a direct on-and-off process: on with the intact S-
conformation, off with the transition to the cleaved R-form. The solving however, of what is a whole 
series of structures of TBG and CBG, has revealed a much more subtle release mechanism. The 
structures show how TBG and CBG have adapted the complex inhibitory mechanism of the serpins to 
differentially regulate the tissue release of thyroxine and corticosteroids. X-Ray crystallography has 
given us single-frame snapshots of frozen structures of TBG and CBG; of the high affinity native S-
forms with an exposed reactive loop and of the lowest affinity cleaved R-forms with a fully incorporated 
reactive loop, as indicated in Figure 1a (Klieber, et al., 2007; Zhou, et al., 2006). However, what matters 
physiologically are the changes in binding affinity that take place in between these two states. These 
changes in binding affinity in circulating CBG and TBG are induced by small movements of the intact 
reactive loop in and out of the body of the molecule (Qi, et al., 2011). The movements of the loop 
although small nevertheless influence the shape and flexibility of the adjacent hormone binding site. 
We can now see how these subtle shifts take place in atomic detail, based on the extensive structural 
studies of another serpin, antithrombin, which has developed a mechanism, closely identical to that of 
CBG, for the binding and release of a heparin pentasccharide (Langdown, et al., 2009).  
Although the modulatory movement of the reactive loop that drives the release mechanism has been 
referred to as a flip-flop shift, it perhaps would have been better to call it nudge-nudge rather than flip-
flop, as it primarily reflects the movement of just a single amino acid residue into and out of the body 
of the molecule (Figure1b). This small modulatory movement of the reactive loop is dynamic, occurring 
constantly and reversibly; with the change in affinity reflecting changes in the relative populations of 
different conformational states. So it is simplistic to expect that such subtle shifts will affect antigenicity 
(Lewis, et al., 2016).  This is not an on-off switching mechanism but rather an equilibrated shift that 
affects the plasticity of the binding-site, and hence allows readily responsive changes in binding avidity.  
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3. Dynamics of Cortisol release 
3.1 Cortisol & thyroxine 
The solving of the structures of TBG and CBG revealed their shared mechanisms for hormone carriage 
and release but along with this came structural hints as to their different missions. The concentration of 
free thyroxine in the plasma is precisely controlled at picomolar levels whereas concentrations of free 
cortisol fluctuate in health over a wide nanomolar range. Thyroxine is bound exceptionally tightly by 
TBG, with only 0.03% of the total blood thyroxine being in the free form. Even small changes in the 
free thyroxine can have profound consequences, an increase of just 40% from the normal concentration 
in blood  can mean thyrotoxicosis and a decrease of similar proportion can constitute hypothyroidism. 
The modulation of thyroxine release is consequently cautious and defined.  The much more ready 
release of cortisol by CBG over a wide range of concentrations is reflected in its reactive loop 
conformation. Whereas the residue in the reactive loop that triggers the release mechanism in TBG 
(Figure 1b), is a threonine with a small side-chain, the residue in the same position in CBG is a bulky 
valine which on entry into the body of the molecule will cause a much greater triggering displacement 
(Klieber, et al., 2007; Zhou, et al., 2006). Metaphorically, CBG as opposed to TBG, could be described 
as trigger happy! 
Physiologically, cortisol levels vary rapidly due to the pulsatile nature of cortisol secretion.  The pattern 
of ultradian (pulsatile) glucocorticoid secretion can be markedly altered by the physiological and 
pathological state (Henley, et al., 2009; Lightman, et al., 2000), and in particular, inflammatory diseases 
are major modifiers of endogenous pulsatile secretion (Gibbison, et al., 2015; Windle, et al., 2001).  
Furthermore, the peak of these secretory pulses may exceed the saturation of CBG (Cameron, et al., 
2010), increasing the height of the ultradian peaks of cortisol.  This can effectively magnify the 
excursion of the pulses (Henley & Lightman, 2011), allowing large pulses of free hormone to occur in 
extravascular tissues such as the brain and subcutaneous tissue (Qi, et al., 2014). This is of relevance 
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because the ultradian rhythm has been shown to be important in glucocorticoid signaling and gene 
transcription (Stavreva, et al., 2009).  
3.2   A Protein Thermocouple 
A major proportion of human metabolism is directed to the precise maintenance of a body temperature 
of 37oC. A prime reason for this closely defined specificity is that the structures of the proteins and 
enzymes controlling vital functions are flexible rather than rigid, with a flexibility that increases with 
temperature. Thus individual proteins have evolved so as to function optimally at the kinetic flexibility 
present at 37oC. This is particularly true of the interactions of proteins with ligands and it was 
predictable that the avidity of binding of cortisol by CBG would decrease with rises in body temperature 
(Mickelson, et al., 1981). There is however a special additional factor contributing to the temperature 
responsiveness of both TBG and CBG. Earlier findings with another serpin, antithrombin, had 
highlighted the temperature dependence of its modulatory mechanism. As with TBG and CBG, the 
mechanism that controls the activity of antithrombin involves small 'nudge-nudge' movements of the 
reactive centre loop into and out of the body of the molecule. The sensitivity of these movements to 
changes in temperature became apparent in patients with mutations in their antithrombin that marginally 
facilitated the entry of the reactive loop (Beauchamp, et al., 1998). The affected individuals remain fit 
and well unless they develop a fever. Then even a small increase in their body temperature, as can occur 
with a minor infection, is sufficient to cause the inactivation of the mutant antithrombin and the 
consequent onset of thrombosis. 
With the precept of antithrombin in mind, an immediate proposal that arose with the solving of the 
structure of TBG was that its hormone release mechanism would be similarly temperature responsive 
(Zhou, et al., 2006). And indeed it proved to be so. Moreover, the temperature responsiveness of TBG 
has clearly evolved to physiological advantage. As shown in Figure 2, TBG effectively functions as a 
protein thermocouple: as body temperature decreases and the basal metabolic rate declines, there will 
be an accompanying increase in binding-affinity and an appropriately decreased release of thyroxine. 
Conversely, when the temperature rises above 37oC, as in fevers, there will be a boosted release of 
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thyroxine, with the equilibrated concentration of free thyroxine at 39oC increasing to near thyrotoxic 
levels. Evidence that this potential boost of thyroxine release in fevers is purposeful, comes from the 
presence in an Australian aboriginal population of an adaptive mutation that turns off the fever-induced 
acceleration of thyroxine release (Qi, et al., 2014). The mutation occurs within the site linking the 
immediate point of entry of the reactive loop into the body of the molecule with the adjacent hormone 
binding pocket (Figure 1b). 
The concept of this thermocouple-like mechanism arose from the solving of the structure of TBG and 
of the S-to-R conformational change in CBG (Zhou, et al., 2008). Experimental confirmation followed  
with recombinant and plasma CBG (Cameron, et al., 2010; Henley & Lightman, 2011) and definitively 
with KD determinations of both intact and cleaved plasma CBG over a range of temperatures (Chan, et 
al., 2013). Not surprisingly, the effect of changes in temperature on the much more sensitive release-
mechanism of CBG is striking (Figure 2). Whereas with TBG there will be a 25%  increase in free 
thyroxine as body temperature rises above 39oC, with CBG there will be a threefold or more increase 
in  free cortisol. These are changes that rapidly re-equilibrate as the temperature rises and falls. A patient 
in fever may have a threefold increase in free cortisol but this will revert almost immediately to a normal 
level as the body is cooled to 37oC. Similarly and  confusingly so, if a blood sample taken during a 
fever is then analysed in the laboratory at 37oC, the result represents what the free cortisol concentration 
is in the blood sample at 37oC  and not what it was in vivo at the time of sampling. 
3.3.     Inflammation and cleavage 
The finding that the cleavage of CBG by neutrophil proteases resulted in a loss of binding-affinity 
initially focused attention on the release of cortisol at foci of inflammation. But a realisation of the 
wider significance of this proteolytic transition has become apparent from a study which defined the 
range of changes in binding-affinity, KD, that can take place in plasma CBG (Chan, et al., 2013). As the 
authors point out, the cleavage of the reactive loop in CBG (Figure 1) results in a large diminution, but 
not a loss of binding affinity. The transition from the intact plasma S-CBG to the cleaved R-CBG is 
accompanied by an increase in KD from 32nM to 292nM, which will result in the release of most of the 
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bound cortisol but by no means all, with the retention by the cleaved R-CBG of a minimal binding 
saturation of 4.3%. The release of cortisol on cleavage of CBG will be most significant in situations 
where blood-flow is sluggish, as in an indurated site of inflammation. In such a compartment, in the 
presence of typical levels of other cortisol-binding proteins, a total cleavage of CBG would result in a 
4-fold spike in free cortisol. This would be accompanied by a re-equilibration of the percentage 
saturation of the cleaved GBG to 16%, a level at which it could effectively buffer the raised free cortisol 
level. If, alternatively, the cleavage of CBG had resulted in a complete loss of cortisol affinity, free 
cortisol would rise to 103 nM, but it would be an unbuffered rise without the backup of a reservoir of 
CBG-bound cortisol.  
The concept that the cleaved and apparently inactivated R-CBG might have a role systemically, as a 
backup buffer to that of the intact circulating S-CBG, has become a reality with the recent development 
of an immunoassay capable of differentiating the two forms of CBG (Lewis & Elder, 2011, 2013). With 
this assay, Lewis and colleagues have shown the half-life of the cleaved R-CBG in the plasma to be the 
same as that of intact S-CBG and also how in severe sepsis the rise in plasma levels of the cleaved form 
can reach near equivalence with that of the intact form (Lewis, et al., 2015; Nenke, et al., 2015). Thus, 
in severe systemic inflammation there will be two major buffering systems: that of intact CBG with a 
high cortisol affinity and that of cleaved CBG with a tenfold lower affinity. The kinetics of the buffered 
release of cortisol in peripheral tissues is complex.  As with most biological systems there is a built-in 
redundancy in the hormone delivery system. CBG has the overwhelming role but it is backed by other 
plasma proteins with much lesser cortisol affinities, namely albumin and orosomucoid (Kerkay & 
Westphal, 1968). The significance of this binding of cortisol by plasma proteins becomes apparent in 
the congenital or induced absence of CBG, leading to a 30% rise in plasma free cortisol but with the 
remainder being substantially bound by albumin (Lewis, et al., 2005). The presence of cleaved CBG, 
which has a much greater affinity for cortisol than that of albumin, will add an intermediate buffer that 
will predictably play a direct as well as backup part in the release of free cortisol in the tissues. 
 3.4 CBG as a Hormone 
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The likelihood of the conformational mechanism of CBG being modified by interactions with tissue-
specific ligands and membrane proteins arises from observations of other plasma serpins. The 
conformation and activity of the serpin inhibitors of coagulation are known to be modified by 
endothelial bound oligosaccharides, as are the serpin controllers of tissue growth by vitronectin and 
other tissue factors. Although such modifying interactions with CBG have not as yet been recognised, 
evidence for its binding to cell membrane sites dates back nearly three decades.  Surface binding sites 
for CBG have been demonstrated in liver, endometrium, placenta, prostate, spleen and kidney 
(Gunaratna, et al., 2004; Hryb, et al., 1986; Maitra, et al., 1993; Singer, et al., 1988; Strel'chyonok & 
Avvakumov, 1991). Membrane binding sites for the plasma steroid-binding proteins share many of the 
general properties of receptors including: binding specificity; time and temperature dependence of 
binding; a dissociation constant approximately equal to the plasma concentration of ligand (Rosner, et 
al., 1988); and evidence for transmembrane signaling with induction of adenylate cyclase in a dose 
dependent manner (Nakhla, et al., 1988).  The latter appears to be cortisol-bound dependent, and since 
cortisol, with a half-life of 60 - 90 minutes, is secreted with a diurnal and ultradian rhythmicity, CBG’s 
activity may be rapidly regulated without changing its plasma concentration.  Further indications of the 
interactions of CBG at a tissue level come from studies of mice with a complete genetic deficiency of 
CBG. Their inability to appropriately respond to the excess of free corticosterone in the absence of CBG 
infers an active role for CBG in the bioavailability, local delivery and/or cellular signal transduction of 
glucocorticoids (Petersen, et al., 2006; Willnow & Nykjaer, 2010). Genetic variants of CBG have also 
been associated with fatigue-pain syndromes and hypotension, suggesting a potential effect of CBG on 
the access of cortisol to brain glucocorticoid receptors (Henley & Lightman, 2011). Overall, these 
findings provide the basis for a novel concept of the mechanisms through which the body regulates 
access of glucocorticoids to the brain and other tissues of the body. However, a cell-surface receptor 
for CBG has not as yet been cloned nor has a tissue-specific ligand been identified.  
 
4. Therapeutic Implications 
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The new understandings of molecular mechanisms of hormone delivery have opened concepts of direct 
relevance to patient management and therapy, along with insights of wider significance in medicine. 
With these come present day questions and challenges. 
4.1  Are assays fit for purpose? 
The new understandings described here require a new mindset; an ability to consider and assess 
corticosteroid status in molecular terms.  To report the concentration of plasma cortisol in nmol/L and 
of CBG in pg/L is meaningless, whereas a CBG of 250 nmol/L with a plasma cortisol of 350 nmol/L 
immediately tells of complete binding-saturation and hence a spiking excess of free cortisol. The 
interpretation of plasma cortisol levels in critically ill patients and the indications for exogenous 
glucocorticoid therapy has been a controversial area in clinical medicine. A major problem has been a 
lack of understanding of the corticosteroid status in these patients. We can now see that a full assessment 
will need the determination of the concentrations of the main carriers of cortisol, including intact CBG, 
cleaved CBG, and albumin. From these values together with the total plasma cortisol and the known 
dissociation constants, the free cortisol will be calculable over a range of body temperatures (Chan, et 
al., 2013; Nguyen, et al., 2014). The direct assay of free cortisol is demanding and very dependent on 
the temperature at which the assay is carried out - best at a rigorously controlled 37oC. Clinicians can 
readily convert the 37oC laboratory result to the level in a pyrexic patient, by doubling the 37oC result 
for a temperature of 38-39oC, and tripling it at 40oC (Figure 3). Nevertheless, while such rule of thumb 
estimates may suffice for everyday clinical management if corticosteroid endocrinology is to advance 
as a medical science a full range of carefully controlled assays will be required. 
A lesson in what not to do, comes from the related area of thyroxine and its release from TBG. The 
unsatisfactory status of assays in this field became apparent in recent studies subsequent to the 
determination of the KD values for TBG over a range of temperatures (Qi, et al., 2014; Qi, et al., 2011). 
Perplexingly, free thyroxine (FT4) concentrations calculated from the newly-determined KD’s were 
consistently higher than quoted literature concentrations. Perusal of the literature also showed a 
disconcerting variation in the quoted 'normal ranges' of FT4 and an inconsistency in defining the 
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demarcations between euthyroid, hypo-, and hyperthyroid function. Enquiries to individual laboratories 
as to their normal ranges were met by evasive replies until obtaining an unpublicised reference-
centre  range (Thienpont, et al., 2010).  It was significantly higher than literature ranges, and satisfyingly 
matched the range determined by calculation from the newly-determined TBG KD values. What became 
clear on further enquiry is that FT4 concentrations have for years been assayed at differing temperatures, 
in many cases listed as 25oC, a frequently used euphemism for that most unscientific of all 
measurements, room temperature! Laboratories and kitset manufacturers have responded to these 
anomalies by adjusting their methodologies, including in some cases standards and controls, to fit with 
what has become not a normal range but a Perceived Normal Range (Christofides & Midgley, 2009; 
Jonklaas, Kahric-Janicic, et al., 2009; Ross & Benraad, 1992; van der Sluijs Veer, et al., 1992). Moves 
are apparently now underway with manufacturers and kitset suppliers to re-calibrate FT4 analyses at 
37oC by 2018. But in the meantime, without accurately defined standards and controls, results in this 
field are dubiously fit for purpose - not adequate for diagnosis or for investigative medicine and 
certainly not for medical science. 
4.2.           Are fevers beneficial? 
A myriad of things will be happen in fever, both to our physiology and to our cellular functions. The 
new understandings described here give us just a glimpse of how in fever bodily processes move into 
overdrive. A rise of just one or two degrees C will automatically raise the plasma FT4 to a concentration 
that in health would move into the hyperthyroid range. With corticosteroids the same increase in 
temperature will lead to a massive release from the circulating store in CBG, to give a threefold increase 
in plasma free cortisol. It is not difficult to see how such increases in active thyroxine and cortisol will 
be of benefit to the body in a crisis. Fever is clearly a universal defensive response to infection and 
inflammation. But it is important that physicians are aware of the accompanying changes in 
corticosteroid availability. The rapid boost to free cortisol levels in pyrexia results from a change in an 
equilibrium that will be immediately reversed on return to normal body temperature. An induced 
cooling of body temperature will lead to a prompt threefold fall in plasma cortisol. Is this good for the 
patient or should it be countered by supplementary corticosteroids? These and other points will need 
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consideration. A first priority in the field however will be to convince physicians of the relevance of 
body temperature in the assessment of corticosteroid status. A free cortisol determined in the laboratory 
at 37oC has only indirect relevance to the actual level in the blood of a pyrexic patient, and a cortisol 
measured at room temperature is only of direct relevance when the patient is dead. 
4.3           Parenteral therapy or hot poultices? 
Good science has a universal applicability, to everyday life as well as to the esoteric; to a falling apple 
as well as to an orbiting planet. The demonstration here of the inherent temperature-dependence of 
hormone release is true, independent of whether the CBG or TBG is in a laboratory cuvette, or a blood 
sample awaiting analysis or, in vivo, in the circulation or tissues. Hence a bonus from the new 
understandings is that they provide a scientific rationale for the age-old use of heat for both bodily 
relaxation and in the treatment of localised pain and inflammation. Active cortisol and thyroxine 
concentrations will rise and fall with body temperature, be it localised or systemic. A hot tub soak can 
raise the whole body temperature to above 39oC (Harvey, et al., 1981) and so, as with Archimedes, 
augment our thoughts and well-being. Focused tissue temperatures can similarly increase with the direct 
application of heat. So therapeutically, the doubling or tripling of localised tissue cortisol levels should 
be readily achievable, without pills or injections, by the application of heating pads, radiant heat or even 
with the hot poultices of our greatgrandmothers' days. 
4.4.         Is induced cortisol-release feasible? 
The full shift in CBG from its high affinity S-form to the low affinity R-form, with a massive release 
of cortisol, takes place on cleavage of the exposed reactive loop of CBG, which becomes irreversibly 
inserted into the main beta-sheet of the molecule, as in Figure 1. A question arising from this is whether 
the conformational transition could be exogenously induced without proteolytic cleavage? The answer 
is encouragingly positive, based on experimental evidence from the very first days of serpin studies, 
when the only structure of an intact serpin was that of the egg-white protein, ovalbumin (Stein, et al., 
1990). These early studies predictably defined the inherent mobility of the reactive centre loop of the 
serpins (Figure 3) and proposed the occurrence of the modulating partial movements of the loop, as 
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described here with CBG and TBG (Carrell, et al., 1991). But what was also shown is that the S-to-R 
conformational transition could be induced by the annealing to the body of the serpin molecule of small 
reactive loop peptide-sequences (Schulze, et al., 1990). In the subsequent years extensive studies have 
been carried out of the use of related small peptides as annealing agents to block the pathological 
polymerisation of another serpin, alpha1-antitrypsin (Parfrey, et al., 2004).  A surprise finding was that 
the polymerisation of alpha1-antitrypsin was efficiently blocked not only by the annealing of reactive 
loop peptides but also by a range of smaller peptides, totally unrelated in sequence (Carrell, et al., 2008). 
Pertinently, these peptides included a four- and a six-residue cholecystokinin neuropeptide present in 
the circulation. X-Ray crystallography showed how the annealing of the cholecystokinin tetrapeptide 
fixes the serpin in its R-conformation: the low-affinity conformation of CBG and TBG (Zhou, et al., 
2004). 
The findings have immediate relevancy to the serpin hormone-carriers. A lesson learnt from the serpins 
as a whole is that evolution has adapted to advantage every facet of their remarkable ability to change 
their shape. A challenge for future research therefore will be to see whether, as seems likely, CBG has 
utilised the potential to interact with small peptides to give a reversible transition to the low-affinity R-
conformation. Conversely these observations also open pharmacological opportunities. Therapeutically 
there is a need to bolster circulatory corticosteroids and the most direct way of achieving this is by 
bolstering the release of cortisol from the large pool bound inertly to CBG. This is achieved naturally 
in inflammation by the proteolytically-induced transition of CGB to its low affinity R-form. The 
possibility of inducing this transition with exogenous small molecules and peptides has been extensively 
explored elsewhere, with the aim of preventing the polymerisation of alpha1-antitrypsin that underlies 
its common genetic deficiency. The challenge with alpha1-antitrypsin is daunting as its polymerisation 
occurs intracellularly. By comparison the possibility of inducing the conformational transition in CBG, 
which is readily accessible in the blood, seems encouragingly achievable. 
 
5.  Targeting drug delivery 
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 A culmination of twenty-five years of studies of individual members of the family has revealed how 
the serpins can uniquely change their shape in order to modulate their function. With this understanding 
comes a challenge. Can the workings of the serpins be adapted for good purpose? Specifically, can the 
ability of the binding-serpins to transport and deliver hormones be tamed to provide a molecular mule: 
a biological made-to-order delivery service? An obvious application is for the tissue-specific delivery 
of drugs, such as cytotoxics, that need to be protectively encapsulated during transport until their release 
in a targeted neoplasm. The feasibility of achieving this has been demonstrated with CBG (Chan, et al., 
2014). Chan and colleagues have shown in principle how recombinant CBG can be engineered to 
provide the preferential binding of a drug and how the modulatory mechanism can be tuned to allow 
the augmented release of the carried drug in target tissues. 
5.1  Engineered binding 
As seen in Figures 1 and 4, cortisol and thyroxine are carried as ligands bound in homologous pockets  
situated between two helices on the surface of their carrier proteins. The pockets have a degree of 
flexibility so the affinity of binding is in part dependent on the fit between the ligand and the carrier 
pocket. Notably however, the side chain of one amino acid in the pocket is critical in contributing to 
the specificity of binding. An arginine in TBG (R381) interacts with the orbiting pi electrons of the 
aromatic rings of thyroxine, while in the same position in CBG the pi orbitals of a tryptophan (W371) 
stack in parallel with the steroid rings of either cortisol or progesterone (Gardill, et al., 2012). The 
significance of the contribution of this single amino acid in the determination of binding specificity has 
been convincingly demonstrated by Chan and colleagues (Chan, et al., 2014) with the engineered 
replacement of the tryptophan in CBG by an arginine (W371R) resulting in a complete loss of affinity 
for cortisol matched with a gained affinity for thyroxine. The mutation effectively converts CBG into a 
TBG! 
Although this single amino acid has a key part in defining the selectivity of binding, the readiness of 
the binding-pocket to independently accommodate a range of small organics and heterocyclic drugs has 
been well demonstrated with TBG (Qi, et al., 2011). Crystallographic structures of the complexes of a 
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series of drugs with TBG illustrate the flexibility of the binding-site, which is seen to contract and adjust 
to embrace the liganded drugs. The observed flexibility of the binding-site and the ready readjustment 
of the primarily hydrophobic bonding that takes place with varied ligands, give confidence as to the 
feasibility of engineering the specificity as well as the affinity of ligand-binding. 
5.2  Targeting and augmented release 
Approaches to the tissue targeting of a carried drug and the preferential triggering of its release are 
summarised in Figure 4. A relaxation of the reactive loop '2', will allow (as shown in '1') the ready entry 
of the side chain of the critical P14 amino acid, with the displacement of an underlying tyrosine and a 
consequent diminution of the flexibility and affinity of the adjacent binding-site. This release 
mechanism is triggered and maximised in vivo when the reactive loop is cleaved at sites of inflammation 
by neutrophil proteases. Chan and colleagues have adapted this proteolytic triggering to provide a tissue 
targeting of ligand release. To achieve this they altered the sequence at the proteolytic cleavage site 
('2'), to change the susceptibility of cleavage from that of neutrophil elastases to that of tissue-specific 
proteases, specifically to the protease associated with prostatic neoplasms, and to the causative protease 
in thrombotic crises. 
The engineering of CBG by Chan and colleagues also shows how increasing the bulk of the side-chain 
of the triggering amino acid (P14,'3' in figure 4) can augment the release of the carried drug or ligand 
at a target-site. This modification of the triggering mechanism is just one approach to boosting the 
release mechanism. Other quite different strategies, proven in vivo, come from the finding of adaptive 
polymorphisms in human populations that in some instances enhance and in others diminish the 
temperature-induced release of ligands. 
5.3  Proof-of-concept to reality 
The pilot demonstration of the adaptation of CBG as a drug delivery vehicle is at proof-of-concept level 
but there is confidence that if required this will be achievable in reality. The serpin framework is robust 
and the manipulated regions are unlikely to give rise to antigenicity, as the binding-site is buried and 
the reactive loop is unstructured. Moreover, tailoring the specificity of binding should be readily 
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possible by random mutation and selection, with the added advantage that crystallographic checking of 
binding can be simply confirmed by crystal soaking (Qi, et al., 2011). There is precedent too for 
parenteral administration, with for a decade or more, thousands of people safely receiving regular 
monthly infusions of the closely related serpin, alpha1-antitrypsin (Stocks, et al., 2010). So reality is 
achievable but till a need arises engineered CBG remains a concept-in-waiting. 
 
6. Overall conclusions 
In reviewing the new structural understandings it is useful to look beyond the mechanistic details to the 
broader significance of the findings. What has been revealed with CBG and TBG is yet another layer 
in the processes that control bodily hormone levels. Here though, the regulation is at tissue level and 
responsively so. The differential secretion of hormones at tissue level has been met by the selection of 
serpins as the carriers of cortisol and of thyroxine. The ready modulation of the conformational 
flexibility of the serpins allows dynamic changes in the plasticity of the hormone-binding site and hence 
of hormone release. Gross examples of this are discussed; there will literally, as well as metaphorically, 
be differences in the free hormone levels between cold-feet and hot-heads! Of greater physiological 
significance however will be the existence of as yet unrecognised tissue receptors and ligands that will 
interact locally to influence the conformational flexibility and hormone avidity of CBG and TBG. 
Overall the understandings we now have of the mechanisms of hormone carriage and release, at atomic 
definition, place corticosteroid- and thyroxine-endocrinology at a forefront of molecular medicine. But 
with this status comes expectations.  The quality of science at this level is dependent on the assays that 
underpin the field; these are currently somewhat inadequate for the cortisol-CBG axis and woefully so 
for thyroxine and TBG. 
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Figure legends 
Figure1. Hormone carriage and release. a. CBG: showing the cortisol binding site and (right) the 
transition from the S- to R-forms on cleavage of the reactive loop in yellow. The cleaved loop moves 
into a stabilising central-strand position in the main beta-sheet of CBG, in red. b. TBG: Indicating the 
small nudging movement of the reactive loop that fine-tunes the binding avidity of the underlying 
thyroxine-binding pocket. Encircled in black on left is the site of the mutation in the Australian 
Aboriginal that abolishes the boost in thyroxine release that otherwise takes place with fever 
temperatures (see Fig 2b). 
 
Figure 2. Temperature responsive hormone release. Plots of the change in ratios of the binding 
affinities (KD/KD(37oC)) with temperature. a. With CBG there will be a near fivefold increase in free 
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cortisol with a rise in body temperature to 42oC; b. with TBG the increase in released thyroxine will be 
much less but its purposeful occurrence is evidenced, dashed line, by a mutation (Fig 1) that negates 
the boosted increase at temperatures above 37oC. 
 
Figure 3. Potential therapy? Serpin conformations as predicted in 1991 from the earliest serpin 
structures. The conformations in a., b. & c. are now seen to be directly relevant to CBG and TBG, and 
d., the induction of the low affinity R-form, by peptide annealing (binary complexing BC) opens the 
potential of the exogenous induction of cortisol release. (Ov. ovalbumin).  Reproduced from Carrell, et 
al. (1991), Nature 353:576-579. 
 
Figure 4. Targeting drug delivery. The focal regions for engineered change are shown on the TBG 
framework. 1. The binding site with thyroxine depicted in sticks. 2. The protease specific cleavage 
sequence in the reactive loop (red). 3. The triggering insertion of P14 as also shown in 1. 
